EP0623023A1 - Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues - Google Patents

Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues

Info

Publication number
EP0623023A1
EP0623023A1 EP93902141A EP93902141A EP0623023A1 EP 0623023 A1 EP0623023 A1 EP 0623023A1 EP 93902141 A EP93902141 A EP 93902141A EP 93902141 A EP93902141 A EP 93902141A EP 0623023 A1 EP0623023 A1 EP 0623023A1
Authority
EP
European Patent Office
Prior art keywords
pyrrole
methyl
carboxyamido
compound
per formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93902141A
Other languages
German (de)
English (en)
Inventor
Federico Arcamone
Paolo Lombardi
Fabio Animati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Original Assignee
A Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Menarini Industrie Farmaceutiche Riunite SRL, Bristol Myers Squibb SpA filed Critical A Menarini Industrie Farmaceutiche Riunite SRL
Publication of EP0623023A1 publication Critical patent/EP0623023A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues preparation of same , and pharmaceutical compositions containing such analogues .
  • the present invention relates to anticancer agents as per general formula ( I )
  • n 0 or a whole number from 1 to 6
  • A a single chemical bond or an alicyclic or aromatic or heterocyclic residue
  • X 1 a chemical bond, the -NHCO- group or the -CONH- group
  • X 2 , X 3 the -CONH- or -NHCO- group and where:
  • R 1 and R 2 (equal) an oxiranomethyl or 1-aziridinomethyl or C 2 -
  • R 4 is C 1 -C 4 alkyl or phenyl
  • R 1 H
  • the invention further refers to the process for the preparation of the aforesaid products, the pharmaceutically acceptable salts thereof, and the pharmacetical compositions containing said products.
  • Dystamicin is an antibiotic already known having formula (A)
  • a requisite for the therapeutic progress in this field is, therefore, the discovery of compounds having molecular characteristics increasing their selectivity in inhibiting the proliferation of viruses and tumoural cells in respect of the healthy ones.
  • An object of this invention is the obtainment of anticancer and antiviral compounds and in particular of dystamicin analogues in which one or more carboxyamidic bonds has/have been replaced by a retrocarboxyamidic bond, containing new chemical modifications at the N-terminal side chain.
  • the said compounds have shown a high anticancer and antiviral activity and a high selectivity in inhibiting tumoural cells and viruses in respect of healthy cells.
  • the compounds as per the present invention are compounds as per general formula (I) and pharmaceutically acceptable salts thereof:
  • n 0 or a whole number from 1 to 6
  • A a single chemical bond or an alicyclic or aromatic or heterocyclic residue
  • X 1 a single chemical bond, the -NHCO- group or the -CONH- group
  • X 2 , X 3 the -CONH- or -NHCO- group and where:
  • R 1 and R 2 (equal) an oxiranomethyl or 1-aziridinomethyl or C 2 -
  • R 4 is C 1 -C 4 alkyl or phenyl
  • R 1 H
  • R 2 -CO-(CH 2 ) m -R 3 , where m is 0 or a whole number from
  • R 3 halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C 2 -C 6 alkenyl group substituted, if required, by halogens or a ketone or an ⁇ ,(S unsaturated alicylic lactone.
  • the invention also refers to pharmaceutical compositions containing the aforesaid compounds or the pharmaceutically acceptable salts therof, based on inorganic acids, e.g. hydrochloric or hydrobromic or sulphuric or nitric acids, etc., or on organic acids, e.g. acetic or propionic or succinic or malonic or citric or tartaric or methanesulfonic or p-toluenesulfonic acids, etc.
  • inorganic acids e.g. hydrochloric or hydrobromic or sulphuric or nitric acids, etc.
  • organic acids e.g. acetic or propionic or succinic or malonic or citric or tartaric or methanesulfonic or p-toluenesulfonic acids, etc.
  • n is as defined above
  • A is a single cyclohexyl or p-phenyl or 1-methylpyrrole or thiophene or thiazole or imidazole or furan or isoxazole or oxazole or triazole or pyridine or pyrrole chemical bond
  • X 1 , X 2 , X 3 are as defined above.
  • the compounds as per general formula (I) may be prepared on the basis of the following processes:
  • n, A. R 1 , R 2 and X 1 are as defined above, or a reactive derivative thereof, with compound as per formula (III)
  • n, A, R 1 , R 2 and X 1 are as defined above, or a reactive precursor of same, with compound as per formula (V)
  • reaction of compound as per formula (II) with compound as per formula (III) was conducted in the presence of condensers, such as DCC (dicyclohexyl carbodiimide) or EDC [1-(3-dimethylaminopro ⁇ yl)-3- ethylcarbodiimide hydrochloride] either in the presence or in the absence of hydroxybenzotriazole or BOP (benzotriazol)-1- yloxytris (dimethylaminophosphonium hexafluorophosphate) or a reactive derivative of (II), such as acylchloride, acylimidazole, acylazide corresponding to acid (II) or an active ester, such as 2,4,5 trichlorophenoxyester or N-oxysuccinimidoester of acid (II) or its anhydride.
  • condensers such as DCC (dicyclohexyl carbodiimide) or EDC [1-(3-
  • reaction of ( II) with (III) is preferably carried out at molar ratios from 1 : 1 to 1 : 3 in an inert organic solvent , such as dimethylsulphoxide , hexamethylphosphorotriamide , dimethylacetamide or preferably dimethylformamide, in the presence of a condenser of the type mentioned above and of N-hydroxybenzotriazole or BOP and in the presence of an organic base , such as triethylamine, diisopropylethylamine and 1 ,8-bis- (dimethylamino) -naphthalene.
  • an inert organic solvent such as dimethylsulphoxide , hexamethylphosphorotriamide , dimethylacetamide or preferably dimethylformamide
  • an organic base such as triethylamine, diisopropylethylamine and 1 ,8-bis- (dimethylamino) -naphthalene.
  • the reaction temperature may range from -10 ° C to 50 °C and the reaction time from 2 to 48 hrs .
  • reaction of compound as per formula (II) with compound as per formula (III) may also be conducted with a reactive derivative of compound as per formula (II) of the type mentioned above in a water- organic solvent biphasic system as for the amidation according to Schotten-Baumann, or in an organic solvent such as benzene, toluene, halogenated hydrocarbons , ethanol , methanol , tetrahydrofuran, dioxane , dimethylformamide , or in aqueous dioxane , ethanol , methanol.
  • a water- organic solvent biphasic system as for the amidation according to Schotten-Baumann
  • organic solvent such as benzene, toluene, halogenated hydrocarbons , ethanol , methanol , tetrahydrofuran, dioxane , dimethylformamide , or in aqueous dioxane , ethanol , methanol.
  • reaction may be carried out also in the presence of an inorganic base, such as a hydroxide, a carbonate or a bicarbonate of an alkali metal , preferably sodium , potassium or barium or an organic base, such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • an inorganic base such as a hydroxide, a carbonate or a bicarbonate of an alkali metal , preferably sodium , potassium or barium or an organic base, such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • an organic base such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • a reactive precursor of compound as per formula (IV) may be e. g. compound having formula (VI)
  • the reaction of an isocyanate as per formula (IV) with an amidino acid as per formula (V) is preferably conducted with an acylazide as per formula (VI) as a reactive precursor of an isocyanate as per formula (IV).
  • the reaction may be carried out in an aromatic hydrocarbon as solvent, such as for example benzene or toluene at 50°C-100°C for 5-20 hrs.
  • a molar quantity of an organic base e.g. triethylamine. pyridine, and the like, may be utilized in the reaction to salify an acid as per formula (V).
  • the process of formation of an isocyanate from a reactive precursor, e.g. an acylazide is well known in organic chemistry (cf. Curtius's reaction).
  • An azide as per formula (VI) may be prepared by causing to react compound as per formula (II) with diphenylphosphorazide or sodium azide (NaN 3 ).
  • R 5 is a typical protective group of carboxylic acids, such as methyl, ethyl, t-butyl, benzyl, 2-trimethylxylylethyl, 2,2,2- trichloroethyl.
  • the hydrolysis of compound as per formula (VII) may be performed according to the methods and procedures known in organic chemisty, as, for instance, referred to in T.W. Greene, Protective Groups in Organic Synthesis, J. Wiley and Sons, Interscience Publishers, 1981.
  • compound as per formula (II), where X 1 , n and A are as defined above and R 1 and R 2 are equal and stand for a C 2 -C 4 alkyl group substituted in position 2 by a halogen or an -OSO 2 R 4 group, where R 4 is as defined above may be prepared, if preferred so, by causing compound as per formula (II), where X 1 , n and A are as defined above and R 1 and R 2 are equal and stand for a C 2 -C 4 alkyl group substituted in position 2 by a hydroxy group, to react with a halogenating agent, e.g.
  • a halogenating agent e.g.
  • R 5 is as defined above.
  • An acid reactive derivative as per formula (VIII) may be the same as that reported hereinabove for compound as per formula (II) and the reaction may be carried out under conditions analogous to those reported for the amidation of compound as per formula (II) with compound as per formula (III).
  • R 1 , R 2 and R 5 are as defined above, are either known [cf. e.g. J. Med. Chem., 32, 774 (1989)] or prepared on the basis of standard procedures starting from known compounds.
  • n, A, and R 5 are as defined above.
  • compound as per formula (IV) may be prepared from a corresponding reactive precursor as per formula (VI) on the basis of Curtius's reaction.
  • An acylazide as per formula (VI) may be prepared from the corresponding acid as per formula (II) on the basis of the methods described in Tetr., 30, 2151 (1974).
  • R 6 is a protective group for a carboxylic acid, such as for example 2,2,2 trichloroethyl, benzyl, phenacyl, and the like, and X 3 is as already defined.
  • the R 6 group may be removed e.g. with Zn in acetic acid or by catalytic hydrogenation on Pd/C in H 2 O, MeOH, EtOH, formic acid and their mixtures.
  • a reactive derivative of compound (XV) may be of the same type as those reported for compounds as per formula (II) and the amidation reaction between (XV) and (XVI) may be carried out as reported above for the reaction between compounds as per formulas (II) and (III).
  • Compounds as per formulas (XV) and (XVI) may be prepared as disclosed in the applicant's Italian Patent N. 22154 dated 22nd Nov. 1990 and referred to here for reference.
  • a reactive precursor of compound ( XVII ) may be a compound as per formula (XIX)
  • R 6 is as defined above .
  • reaction of an isocyanate as per formula (XVII) with an acid as per formula (XVIII) may preferably be conducted using an azide as per formula (XIX) as reactive precursor of (XVII) under conditions analogous to those reported above for the reaction of compound as per formula (VI) with compound as per formula (V) .
  • the present invention further refers to pharmaceutical compositions containing as active ingredient a compound as per formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable vector or diluent.
  • a therapeutically effective amount of compound as per formula (I) according to the invention is combined with an inert and pharmaceutically acceptable vector.
  • the vectors used may be the traditional ones and the compositions may be formulated according to the usual methods .
  • the compounds as per the present invention are useful for the therapeutic treatment of humans and animals .
  • the compounds as per the Invention are useful as antitumoural and/or antiviral agents when administered in therapeutically effective amounts , e.g. an adequate dosage for adult administration may range from 0.1 to 100 mg approx. pro dose from 1 to 4 times /day.
  • X 3 -CONH-) (190 mg; 0.469 mM), 63 mg of N- hydroxybenzotriazole (H0BT) (0.469 mM), 103 mg of 1,8-bis- (dimethylamino)-naphthalene (0.480 mM) and by subsequent additions [1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) (162 mg; 0.848 mM) .
  • H0BT N- hydroxybenzotriazole
  • EDC 1,8-bis- (dimethylamino)-naphthalene

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composés répondant à la formule générale (I), et leurs sels pharmaceutiquement acceptables, pouvant être utilisés comme agents anticancéreux et antiviraux.
EP93902141A 1992-01-10 1993-01-04 Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues Withdrawn EP0623023A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI920021A IT1262921B (it) 1992-01-10 1992-01-10 Agenti antitumorali analoghi di oligopeptidi pirrol-amidinici retroversi processi di preparazione e prodotti farmaceutici che li contengono
ITMI92021 1992-01-10
PCT/EP1993/000002 WO1993013739A2 (fr) 1992-01-10 1993-01-04 Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues

Publications (1)

Publication Number Publication Date
EP0623023A1 true EP0623023A1 (fr) 1994-11-09

Family

ID=11361495

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93902141A Withdrawn EP0623023A1 (fr) 1992-01-10 1993-01-04 Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues

Country Status (4)

Country Link
EP (1) EP0623023A1 (fr)
AU (1) AU3347893A (fr)
IT (1) IT1262921B (fr)
WO (1) WO1993013739A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271456B (it) * 1993-03-01 1997-05-28 Menarini Farma Ind Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
IT1263089B (it) * 1993-04-26 1996-07-24 Menarini Farma Ind Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
US5808087A (en) * 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
MXPA02000253A (es) * 1999-07-01 2002-06-21 Ajinomoto Kk Compuestos heterociclicos y uso medico de los mismos.
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
KR20030043785A (ko) 2000-03-16 2003-06-02 젠소프트, 인크. 핵산 결합 부위를 포함하는 하전된 화합물 및 이의 용도
US7122626B2 (en) 2001-04-26 2006-10-17 Genesoft Pharmceuticals, Inc. Halogen-substitued thienyl compounds
AU2002312370A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Antipathogenic benzamide compounds
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
WO2004039318A2 (fr) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Composes biaryle anti-infectieux
CA2508769A1 (fr) 2002-12-10 2004-06-24 Oscient Pharmaceuticals Corporation Composes antibacteriens possedant un motif (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6461040D0 (pt) * 1963-07-26 1973-08-02 Farmaceutici Italia Processo para preparar novos derivados de pirrol
CN85103908A (zh) * 1985-07-16 1986-11-05 法米塔利·卡洛·埃尔巴有限公司 制备4′-表多克索红菌素的新方法
AT387013B (de) * 1985-07-16 1988-11-25 Erba Farmitalia Verfahren zur herstellung von poly-4-aminopyrrol -2-carboxamidoderivaten
GB8612218D0 (en) * 1986-05-20 1986-06-25 Erba Farmitalia Site specific alkylating agents
GB8906709D0 (en) * 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9313739A3 *

Also Published As

Publication number Publication date
WO1993013739A3 (fr) 1993-11-25
ITMI920021A0 (it) 1992-01-10
IT1262921B (it) 1996-07-22
WO1993013739A2 (fr) 1993-07-22
AU3347893A (en) 1993-08-03
ITMI920021A1 (it) 1993-07-10

Similar Documents

Publication Publication Date Title
US20200181115A1 (en) Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative
US5589490A (en) Benzoic acid substituted derivatives having cardiovascular activity
CN101203519A (zh) 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物
WO1993013739A2 (fr) Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues
US20230312557A1 (en) P2x3 modulators
HU211680A9 (en) Pyrazolopyridine compounds which have useful pharmaceutical utility
JP2001513767A (ja) メタロプロテアーゼ阻害剤としての逆ヒドロキサメート誘導体
EP3983387B1 (fr) Dérivés de sulfonylurée et leurs utilisations
US4431663A (en) Treatment of psychosis with meta-sulfonamido-benzamide derivatives
CA2240594C (fr) Derives de 2,7-octahydro substitue-pyrrolo¬1,2-a|pyrazine
JPS63275561A (ja) 置換ピロール類
JP2003509417A (ja) トリプターゼインヒビター
NO885117L (no) Substituerte hydroksylaminer.
WO2002098839A1 (fr) Biphenylcarboxamides et procede de preparation de ceux-ci
US12297193B2 (en) PTPN2/PTP1B degrader and therapeutic method thereof
WO1992009574A2 (fr) Derives polyaminopyrrolecarboxamido, leurs procedes de preparation et compositions pharmaceutiques les contenant
SG11202107653RA (en) Carbamate derivatives and uses thereof
US8980938B2 (en) CXCR2 inhibitors
EP1819704B1 (fr) Derive amide de l'acide pyrrolopyridine-2-carboxylique utile en tant qu'inhibiteur de la glycogene-phosphorylase
EP0812838A1 (fr) Derive d'acide pyridonecarboxylique substitue par un groupe amino bicyclique, ester et sel de celui-ci, et amine bicyclique utilisee en tant qu'intermediaire pour celui-ci
EP0663395B1 (fr) Dérivés de 3-(phénylalkylaminoalkyloxy)-5-phénylpyrazole, procédé et intermédiaires pour leur préparation et leur utilisation comme agent de réduction du rythme cardiaque
CN101809014A (zh) 吡唑-3-基-苯甲酰胺衍生物的制造方法
US4650868A (en) 7-deazapurine derivatives useful as antitumor agents
JPH01313460A (ja) Ｎ‐置換されたｎ‐アミノ‐ピロール
JP3376479B2 (ja) 縮合ピリミジン誘導体、その製造法および用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970801